Terms: = Ovarian cancer AND DCTN1, DAP-150, 1639, ENSG00000204843, Q14203, P135, DP-150
13 results:
1. Predictive Value of Machine Learning for Platinum Chemotherapy Responses in ovarian cancer: Systematic Review and Meta-Analysis.
Wang Q; Chang Z; Liu X; Wang Y; Feng C; Ping Y; Feng X
J Med Internet Res; 2024 Jan; 26():e48527. PubMed ID: 38252469
[TBL] [Abstract] [Full Text] [Related]
2. RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma.
Kim K; Kim SH; Lee JY; Kim YN; Lee ST; Park E
J Gynecol Oncol; 2023 Jul; 34(4):e45. PubMed ID: 36807748
[TBL] [Abstract] [Full Text] [Related]
3. [Analysis of PARP inhibitors induced anemia in advanced and relapsed epithelial ovarian cancer].
Zeng J; Li N; Yuan GW; Sun YC; Zhang R; Li XG; Zuo J; Li N; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):401-407. PubMed ID: 34154315
[No Abstract] [Full Text] [Related]
4. CD70 antibody-drug conjugate: A potential novel therapeutic agent for ovarian cancer.
Shiomi M; Matsuzaki S; Serada S; Matsuo K; Mizuta-Odani C; Jitsumori M; Nakae R; Matsuzaki S; Nakagawa S; Hiramatsu K; Miyoshi A; Kobayashi E; Kimura T; Ueda Y; Yoshino K; Naka T; Kimura T
Cancer Sci; 2021 Sep; 112(9):3655-3668. PubMed ID: 34117815
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of universal screening in major lynch-associated tumors: a systematic review of literature.
Kunnackal John G; Das Villgran V; Caufield-Noll C; Giardiello FM
Fam Cancer; 2022 Jan; 21(1):57-67. PubMed ID: 33426601
[TBL] [Abstract] [Full Text] [Related]
6. Analysis of MRI Values and Hemoglobin and Total Protein Concentrations of Cystic ovarian Tumors.
Tanaka Y; Nakai G; Yamamura K; Yamamoto K; Narumi Y; Ohmichi M
J Magn Reson Imaging; 2019 Apr; 49(4):1133-1140. PubMed ID: 30240525
[TBL] [Abstract] [Full Text] [Related]
7. Validating the IBIS and BOADICEA Models for Predicting Breast cancer Risk in the Iranian Population.
Ghoncheh M; Ziaee F; Karami M; Poorolajal J
Clin Breast Cancer; 2017 Jun; 17(3):e113-e118. PubMed ID: 28216418
[TBL] [Abstract] [Full Text] [Related]
8. ovarian preservation in young patients with stage I cervical adenocarcinoma: a surveillance, epidemiology, and end results study.
Lyu J; Sun T; Tan X
Int J Gynecol Cancer; 2014 Oct; 24(8):1513-20. PubMed ID: 25188889
[TBL] [Abstract] [Full Text] [Related]
9. Quality of life in female cancer survivors: is it related to ovarian reserve?
Kondapalli LA; Dillon KE; Sammel MD; Ray A; Prewitt M; Ginsberg JP; Gracia CR
Qual Life Res; 2014 Mar; 23(2):585-92. PubMed ID: 23881516
[TBL] [Abstract] [Full Text] [Related]
10. Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer.
Chiara S; Tognoni A; Pastrone I; Tomasello L; Brema F; Di Costanzo G; Folco U; Pronzato P;
Gynecol Oncol; 2004 May; 93(2):474-8. PubMed ID: 15099965
[TBL] [Abstract] [Full Text] [Related]
11. Extrauterine low-grade endometrial stromal sarcoma: report of three cases.
Fukunaga M; Ishihara A; Ushigome S
Pathol Int; 1998 Apr; 48(4):297-302. PubMed ID: 9648159
[TBL] [Abstract] [Full Text] [Related]
12. Computerized tomography of the abdomen and pelvis with peritoneal administration of soluble contrast (IPC-CT) in detection of residual disease for patients with ovarian cancer.
Frasci G; Contino A; Iaffaioli RV; Mastrantonio P; Conforti S; Persico G
Gynecol Oncol; 1994 Feb; 52(2):154-60. PubMed ID: 8314132
[TBL] [Abstract] [Full Text] [Related]
13. [Analysis of serum CA125, CEA, AFP, LDH levels and LDH isoenzymes in patients with ovarian tumors--correlation between tumor markers and histological types of ovarian tumors].
Konishi I; Fujii S; Okamura H; Sakahara H; Endo K; Torizuka K; Suzuki A; Mori T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):827-36. PubMed ID: 2426374
[TBL] [Abstract] [Full Text] [Related]
